• LAST PRICE
    4.4400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    4.2500/ 1
  • Ask / Lots
    4.5000/ 1
  • Open / Previous Close
    0.0000 / 4.4400
  • Day Range
    ---
  • 52 Week Range
    Low 3.6500
    High 8.6400
  • Volume
    200
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 4.5839
TimeVolumeENLV
09:32 ET11664.4
09:42 ET1004.4545
09:55 ET7004.5199
10:26 ET3004.42
10:29 ET3004.445
10:31 ET1004.46
10:36 ET1754.46
10:40 ET10004.4483
10:54 ET1104.4404
11:09 ET24814.47
11:21 ET3004.4143
11:36 ET1004.54
11:43 ET1004.54
11:45 ET1004.54
11:50 ET1004.54
11:54 ET1004.53
12:01 ET1004.52
12:12 ET1004.5199
12:30 ET1004.45
12:35 ET1004.45
12:48 ET2184.44
02:02 ET50624.585
02:03 ET1004.68
02:07 ET5004.545
02:21 ET23204.51
02:25 ET12004.55
02:50 ET1004.55
02:52 ET1004.555
03:01 ET1004.55
03:15 ET1004.54
03:19 ET1004.55
03:21 ET1004.55
03:26 ET1004.55
03:37 ET10454.55
03:39 ET1004.545
03:46 ET8504.44
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesENLV
Enlivex Therapeutics Ltd
81.7M
-3.1x
---
United StatesMYMD
MyMD Pharmaceuticals Inc
82.5M
-5.5x
---
United StatesDARE
Dare Bioscience Inc
80.6M
-2.6x
---
United StatesIOBT
IO Biotech Inc
84.7M
-1.2x
---
United StatesHCWB
HCW Biologics Inc
78.0M
-6.2x
---
United StatesVACC
Vaccitech PLC
84.7M
6.1x
---
As of 2022-12-02

Company Information

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Contact Information

Headquarters
14 Einstein St.NESS-ZIONA, Israel 7403618
Phone
---
Fax
---

Executives

Chief Executive Officer
Oren Hershkovitz
Executive Chairman of the Board
Shai Novik
Founder, Chief Scientific Officer and Medical Officer
Dror Mevorach
Chief Financial Officer
Shachar Shlosberger
Director
Baruch Halpert

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$81.7M
Revenue (TTM)
$0.00
Shares Outstanding
18.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.99
EPS
$-1.43
Book Value
$4.64
P/E Ratio
-3.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.